Together, these results suggest that OHT administration may be an effective treatment for obesity, helping weight loss either through a direct action on CB1 or through an alternative pathway involving PPARγ that results in CB1 inhibition. This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.